v3.26.1
Balance Sheet Accounts
 9 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Accounts BALANCE SHEET ACCOUNTS
Property, Plant and Equipment
The following table summarizes the Company’s major classes of property, plant and equipment:
June 30, 2026September 30, 2025
(in thousands)
Land$2,995 $2,996 
Buildings254,859 251,317 
Research equipment61,447 62,758 
Manufacturing equipment34,182 18,588 
Furniture5,813 5,594 
Computers and software971 1,064 
Leasehold improvements104,462 104,425 
Construction in progress5,811 15,942 
Property, plant and equipment, gross470,540 462,684 
Less: Accumulated depreciation and amortization(97,239)(80,169)
Property, plant and equipment, net$373,301 $382,515 
Depreciation and amortization expense for property, plant and equipment for the three months ended June 30, 2026 and 2025 was $6.2 million and $5.8 million, respectively. Depreciation and amortization expense for property, plant and equipment for the nine months ended June 30, 2026 and 2025 was $18.1 million and $16.2 million, respectively.

Accrued Expenses
Accrued expenses consisted of the following as of:
June 30, 2026September 30, 2025
(in thousands)
Accrued research and development expenses
$35,648 $30,330 
Accrued research and development expenses; co-development36,368 31,296 
Accrued capital expenditures1,084 277 
Accrued income taxes— 20,799 
Dividends declared by variable interest entity to noncontrolling shareholders2,110 — 
Other10,964 7,717 
Total accrued expenses$86,174 $90,419 
As of June 30, 2026, the Company’s accrued research and development expenses were primarily attributable to ongoing clinical trial operations, preclinical animal studies, and associated toxicology assessments. Research and development expenses related to co-development and co-commercialization activities per the Takeda License Agreement are reported as accrued research and development expenses; co-development in the table above (see Note 2).